A 33-year-old woman with a 10-year history of MS disease was treated with several DMTs such as beta-interferon, natalizumab, fingolimod, and alemtuzumab, before switching to ocrelizumab on October 16, 2019. This evidence concerns the gene IFNB1 and myeloid sarcoma.